Viewing Study NCT00127257



Ignite Creation Date: 2024-05-05 @ 11:45 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00127257
Status: COMPLETED
Last Update Posted: 2010-01-13
First Post: 2005-08-04

Brief Title: Biofeedback for Dyssynergic Constipation
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK

Study Overview

Official Title: Biofeedback for Fecal Incontinence and Constipation
Status: COMPLETED
Status Verified Date: 2010-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Constipation affects 4 of adults in the United States US An estimated half of constipated patients are unable to relax pelvic floor muscles during defecation a type of constipation called pelvic floor dyssynergia PFD Biofeedback has been recommended for the treatment of constipation because uncontrolled studies over the past 10 years suggest that these treatments are as effective as medical or surgical management and involve no risk However placebo-controlled trials are still lacking The aims of this study are

to compare biofeedback to alternative therapies for which patients have a similar expectation of benefit
to identify which patients are most likely to benefit and
to assess the impact of treatment on quality of life
Detailed Description: This study is a long-term prospective single-blind study comparing biofeedback for pelvic floor dyssynergia to a skeletal muscle relaxant drug diazepam 5 mg two hours before attempted defecation and to placebo medication Prior to randomization patients will first receive medical therapy laxatives and education for 4 weeks and only those remaining constipated will be randomized Physiological tests of anal canal pressure during straining to defecate and ability to pass a 50-ml air filled balloon will be tested before and after treatment Patients will keep a diary throughout baseline and treatment and they will be reassessed at 3 6 and 12 months follow-up Treatment will consist of 6 clinic visits at 2-week intervals The investigators will develop a detailed treatment manual for this disorder which would permit other investigators to replicate their study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None